To evaluate the safety and clinical activity of BI 905711 alone or in combination with chemotherapy in advanced gastrointestinal cancers.
Phase I clinical trial design
Monotherapy with BI 905711
Combination therapy with FOLFIRI and bevacizumab
Assessment of safety and efficacy profiles
Managed safety profile observed in both treatment groups
Limited clinical activity noted for BI 905711 monotherapy and combination therapy
Heavily pretreated patient population showed similar outcomes across treatments
Abstract
In heavily pretreated patients with GI tumors, BI 905711 monotherapy or with FOLFIRI plus bevacizumab displayed a manageable safety profile and limited clinical activity.